| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 2106.57% | HC Wainwright & Co. | $35 → $47 | Maintains | Buy |
| 08/11/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 06/05/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/30/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 05/11/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
| 04/28/2023 | 557.28% | Ladenburg Thalmann | $8 → $14 | Maintains | Buy |
| 03/23/2023 | 181.69% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 03/23/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 02/08/2023 | 1543.19% | HC Wainwright & Co. | → $35 | Maintains | Buy |
| 09/15/2022 | 275.59% | Ladenburg Thalmann | → $8 | Initiates Coverage On | → Buy |
| 05/16/2022 | 1543.19% | HC Wainwright & Co. | $51 → $35 | Maintains | Buy |
| 10/21/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/13/2021 | 2294.37% | HC Wainwright & Co. | → $51 | Initiates Coverage On | → Buy |
| 07/06/2021 | 979.81% | Piper Sandler | → $23 | Initiates Coverage On | → Overweight |
What is the target price for Tempest Therapeutics (TPST)?
The latest price target for Tempest Therapeutics (NASDAQ: TPST) was reported by HC Wainwright & Co. on October 11, 2023. The analyst firm set a price target for $47.00 expecting TPST to rise to within 12 months (a possible 2106.57% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tempest Therapeutics (TPST)?
The latest analyst rating for Tempest Therapeutics (NASDAQ: TPST) was provided by HC Wainwright & Co., and Tempest Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Tempest Therapeutics (TPST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tempest Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tempest Therapeutics was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
Is the Analyst Rating Tempest Therapeutics (TPST) correct?
While ratings are subjective and will change, the latest Tempest Therapeutics (TPST) rating was a maintained with a price target of $35.00 to $47.00. The current price Tempest Therapeutics (TPST) is trading at is $2.13, which is out of the analyst's predicted range.